Nifty
Sensex
:
:
10961.85
36578.96
54.90 (0.50%)
192.35 (0.53%)

Pharmaceuticals & Drugs

Rating :
72/99

BSE: 532321 | NSE: CADILAHC

344.60
-2.45 (-0.71%)
21-Jan-2019 | 3:57PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  345.95
  •  351.70
  •  343.55
  •  347.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  786496
  •  2710.27
  •  445.00
  •  332.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 35,523.87
  • 17.66
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 39,615.67
  • 1.01%
  • 3.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.79%
  • 1.41%
  • 5.60%
  • FII
  • DII
  • Others
  • 3.68%
  • 5.46%
  • 9.06%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.06
  • 10.51
  • 8.09

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.11
  • 18.85
  • 3.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.24
  • 16.34
  • -3.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.32
  • 26.81
  • 25.27

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.29
  • 6.47
  • 5.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.76
  • 18.93
  • 18.35

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
2,961.20
3,221.90
-8.09%
2,893.70
2,234.80
29.48%
3,250.20
2,513.30
29.32%
3,259.60
2,363.80
37.90%
Expenses
2,273.40
2,364.80
-3.87%
2,248.70
1,958.10
14.84%
2,379.80
2,048.80
16.16%
2,418.40
1,959.50
23.42%
EBITDA
687.80
857.10
-19.75%
645.00
276.70
133.10%
870.40
464.50
87.38%
841.20
404.30
108.06%
EBIDTM
23.23%
26.60%
22.29%
12.38%
26.78%
18.48%
25.81%
17.10%
Other Income
30.40
22.50
35.11%
101.30
21.00
382.38%
28.70
73.10
-60.74%
41.10
16.60
147.59%
Interest
35.70
40.50
-11.85%
35.00
21.80
60.55%
15.40
9.80
57.14%
13.50
6.60
104.55%
Depreciation
147.50
126.30
16.79%
141.80
121.60
16.61%
144.00
114.10
26.21%
147.30
89.80
64.03%
PBT
535.00
712.80
-24.94%
569.50
154.30
269.09%
739.70
413.70
78.80%
721.50
324.40
122.41%
Tax
124.70
212.30
-41.26%
120.30
29.30
310.58%
144.20
1.90
7,489.47%
178.60
8.10
2,104.94%
PAT
410.30
500.50
-18.02%
449.20
125.00
259.36%
595.50
411.80
44.61%
542.90
316.30
71.64%
PATM
13.86%
15.53%
15.52%
5.59%
18.32%
16.38%
16.66%
13.38%
EPS
4.08
4.92
-17.07%
4.50
1.35
233.33%
5.77
3.76
53.46%
5.30
3.16
67.72%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
12,364.70
11,904.90
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
3,686.80
2,927.50
Net Sales Growth
19.65%
26.97%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
25.60%
25.94%
 
Cost Of Goods Sold
4,186.40
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
1,011.20
839.40
Gross Profit
8,178.30
8,248.00
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
2,675.60
2,088.10
GP Margin
66.14%
69.28%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
72.57%
71.33%
Total Expenditure
9,320.30
9,076.30
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
2,878.20
2,344.40
Power & Fuel Cost
-
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
66.00
49.90
% Of Sales
-
1.90%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
1.79%
1.70%
Employee Cost
-
1,820.30
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
401.10
310.90
% Of Sales
-
15.29%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
10.88%
10.62%
Manufacturing Exp.
-
1,197.50
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
429.10
345.20
% Of Sales
-
10.06%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
11.64%
11.79%
General & Admin Exp.
-
509.50
466.00
432.70
326.80
365.70
342.20
271.90
234.90
218.50
172.20
% Of Sales
-
4.28%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
5.93%
5.88%
Selling & Distn. Exp.
-
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
585.30
477.70
% Of Sales
-
8.52%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
15.88%
16.32%
Miscellaneous Exp.
-
651.30
502.60
561.80
417.40
310.30
157.40
185.90
166.00
167.00
477.70
% Of Sales
-
5.47%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
4.53%
5.09%
EBITDA
3,044.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
808.60
583.10
EBITDA Margin
24.62%
23.76%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
21.93%
19.92%
Other Income
201.50
133.00
147.10
116.60
57.20
58.00
38.40
53.00
22.80
15.90
20.40
Interest
99.60
110.80
63.10
52.80
67.90
90.20
168.70
182.70
69.90
82.10
97.80
Depreciation
580.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
133.90
111.80
PBT
2,565.70
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
608.50
393.90
Tax
567.80
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
74.10
66.60
Tax Rate
22.13%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
12.27%
18.01%
PAT
1,997.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
506.00
294.90
PAT before Minority Interest
1,962.10
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
529.80
303.20
Minority Interest
-35.80
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
-23.80
-8.30
PAT Margin
16.16%
14.39%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
13.72%
10.07%
PAT Growth
47.60%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
40.51%
71.58%
 
Unadjusted EPS
19.65
17.35
14.53
19.19
11.24
39.25
31.92
31.87
34.73
24.67
22.20

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
1,628.50
1,235.20
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
68.20
68.20
Total Reserves
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
1,560.30
1,167.00
Non-Current Liabilities
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
1,204.60
1,398.90
Secured Loans
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
978.20
1,068.40
Unsecured Loans
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
112.30
198.90
Long Term Provisions
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
0.00
0.00
Current Liabilities
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
871.10
691.60
Trade Payables
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
619.60
525.60
Other Current Liabilities
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
56.40
47.40
Short Term Borrowings
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
0.00
0.00
Short Term Provisions
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
195.10
118.60
Total Liabilities
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
3,348.50
Net Block
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
1,684.40
1,529.80
Gross Block
9,338.50
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
2,557.80
2,287.00
Accumulated Depreciation
2,842.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
835.00
719.90
Non Current Assets
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
1,953.30
1,743.60
Capital Work in Progress
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
211.10
155.50
Non Current Investment
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
20.70
24.90
Long Term Loans & Adv.
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
0.00
0.00
Other Non Current Assets
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
1,779.90
1,561.10
Current Investments
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
0.00
0.00
Inventories
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
750.40
601.20
Sundry Debtors
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
466.80
454.90
Cash & Bank
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
250.70
251.70
Other Current Assets
1,048.40
80.00
124.10
70.70
323.50
345.90
332.00
253.00
312.00
253.30
Short Term Loans & Adv.
730.10
268.50
234.80
240.80
254.90
279.00
274.60
206.20
308.00
251.40
Net Current Assets
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
908.80
869.50
Total Assets
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
3,348.50

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
695.40
218.60
PBT
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
603.90
369.80
Adjustment
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
228.10
200.30
Changes in Working Capital
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
-123.60
-121.00
Cash after chg. in Working capital
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
708.40
449.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-620.60
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
-77.10
-48.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
-12.50
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
-371.60
-409.50
Net Fixed Assets
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
-223.80
-138.40
Net Investments
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
-3.50
-152.70
Others
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
-144.30
-118.40
Cash from Financing Activity
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
-324.80
349.60
Net Cash Inflow / Outflow
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
-1.00
158.70
Opening Cash & Equivalents
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
251.70
92.60
Closing Cash & Equivalent
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20
250.70
251.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
15.82
11.65
ROA
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
14.94%
10.28%
ROE
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
37.71%
26.91%
ROCE
18.41%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
26.55%
21.46%
Fixed Asset Turnover
1.37
1.38
1.76
1.80
1.63
1.55
1.58
1.75
1.54
1.42
Receivable days
83.84
76.72
63.29
56.38
51.71
52.78
57.47
47.97
45.13
49.59
Inventory Days
64.05
59.88
54.52
60.13
63.89
64.82
64.85
60.83
66.19
65.73
Payable days
71.22
74.18
67.53
55.78
50.51
43.54
49.87
64.40
75.83
73.08
Cash Conversion Cycle
76.67
62.42
50.28
60.73
65.09
74.05
72.45
44.40
35.49
42.24
Total Debt/Equity
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
0.67
1.06
Interest Cover
21.87
26.55
40.75
22.29
11.45
5.79
5.35
13.05
8.36
4.78

News Update:


  • Zydus Cadila gets USFDA’s tentative approval for Esomeprazole Capsules
    21st Jan 2019, 14:53 PM

    It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets USFDA’s final nod for Acetazolamide ER Capsules
    17th Jan 2019, 11:22 AM

    The group now has 246 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila gets USFDA’s final approval for Betamethasone Dipropionate Cream
    14th Jan 2019, 09:09 AM

    The group also received a final approval for Amlodipine and Atorvastatin Tablets

    Read More
  • Zydus Cadila gets USFDA’s nod for Aripiprazole Tablets
    8th Jan 2019, 12:05 PM

    The group now has 243 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus receives approval from USFDA for Clindamycin Phosphate and Benzoyl Peroxide Gel
    31st Dec 2018, 09:32 AM

    Clindamycin is an antibiotic that stops the growth of acne-causing bacteria

    Read More
  • Zydus gets USFDA’s nods for Doxycycline Hyclate Delayed-Release Tablets, Febuxostat Tablets
    24th Dec 2018, 11:22 AM

    The group now has 241 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus receives approvals from USFDA for Albendazole Tablets
    15th Dec 2018, 15:39 PM

    The company has also received approval for Pregabalin Capsules

    Read More
  • Cadila Healthcare’s arm receives approval from USFDA for Ranitidine Injection
    11th Dec 2018, 12:12 PM

    Ranitidine belongs to the class of medications called H2-antagonists and is used to treat stomach and duodenal (intestinal) ulcers, and prevent them from recurring

    Read More
  • Cadila Healthcare enters into agreement with Zydus Wellness
    7th Dec 2018, 09:52 AM

    The company to subscribe to 85,02,170 equity shares at an issue price of Rs 1,382

    Read More
  • Zydus Cadila gets USFDA’s final approval for Teriflunomide Tablets
    3rd Dec 2018, 09:23 AM

    Teriflunomide is used to treat relapsing forms of MS

    Read More
  • Zydus Cadila gets USFDA’s final approval for Lansoprazole Tablets
    29th Nov 2018, 12:21 PM

    The company has also received USFDA’s tentative approval for Linagliptin tablets, 5 mg

    Read More
  • Zydus receives final approval from USFDA for Baclofen Tablets
    27th Nov 2018, 14:05 PM

    It works by helping to relax the muscles

    Read More
  • Zydus gets USFDA’s nod for Atorvastatin Calcium Tablets, Dimethyl Fumarate Delayed-Release Capsules
    22nd Nov 2018, 14:16 PM

    The group now has 233 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila receives tentative approval from USFDA for Deferasirox Tablets
    20th Nov 2018, 12:32 PM

    It is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions

    Read More
  • Zydus Cadila receives USFDA’s approval for Abacavir & Lamivudine Tablets, Fondaparinux Sodium Injection
    16th Nov 2018, 14:13 PM

    Abacavir and Lamivudine Tablets are used with other antiretroviral medicines to treat HIV-1 infection

    Read More
  • Zydus Cadila receives approval from USFDA for Arsenic Trioxide Injection
    14th Nov 2018, 15:54 PM

    Arsenic Trioxide is used to treat a type of leukemia when other types of treatment have not worked well or no longer work

    Read More
  • Zydus Cadila gets USFDA’s approval for Nystatin and Triamcinolone Acetonide Ointment
    12th Nov 2018, 11:12 AM

    It will be manufactured at the group's Topical manufacturing facility at Ahmedabad

    Read More
  • Cadila Healthcare reports 17% fall in Q2 consolidated net profit
    5th Nov 2018, 11:59 AM

    Total consolidated income of the company decreased by 7.79% at Rs 2,991.60 crore for Q2FY19

    Read More
  • Cadila Healthcare - Quarterly Results
    3rd Nov 2018, 12:48 PM

    Read More
  • Zydus Cadila gets USFDA’s nod for Vardenafil Hydrochloride tablets, Ursodiol tablets
    1st Nov 2018, 12:24 PM

    The group now has 226 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04

    Read More
  • Cadila Healthcare subscribes 51% stake in Windlas
    30th Oct 2018, 09:52 AM

    With this, Windlas has become a subsidiary of the company

    Read More
  • Zydus Cadila gets final approval from USFDA for Clobazam Tablets
    23rd Oct 2018, 14:16 PM

    It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila receives approval from USFDA for Colchicine Tablets
    19th Oct 2018, 09:00 AM

    An attack of gout occurs when uric acid causes inflammation in a joint

    Read More
  • Zydus Cadila gets final approval from USFDA for Clobetasol Propionate Cream
    17th Oct 2018, 14:47 PM

    It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.